Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?

Those who develop effusion after some time lag form the initial treatment, will have a poor survival (median four months) compared to those who had effusion at the start of the disease.

📌 3 Maddede Bu Makale

🎯

Amaç & Hipotez:Malignant pleural effusion in myeloma (MMPE) is a rare terminal event; with a median survival is four months.

📊

Temel Bulgular & Veri:All the patients usually have multiple poor prognostic factors and none of them (like beta 2-microglobulin, karyotype, Stage of disease, C-reactive protein etc.) correctly predicts the survival.

💡

Sonuç & Katkı:Those who develop effusion after some time lag form the initial treatment, will have a poor survival (median four months) compared to those who had effusion at the start of the disease.

🔬Tür:Literatür & Derleme Çalışması

📍Kapsam:Genişletilmiş Akademik Örneklem

⚙️Değişkenler:Plevral efüzyon · Ölümle sonuçlanma · Yaşlı

Özet

Malignant pleural effusion in myeloma (MMPE) is a rare terminal event; with a median survival is four months. All the patients usually have multiple poor prognostic factors and none of them (like beta 2-microglobulin, karyotype, Stage of disease, C-reactive protein etc.) correctly predicts the survival. We are reporting a series of five cases and evaluated the factors influencing the overall survival. All of our patients had a very good response to treatment and had a better survival compared to the reported cases so far. After reviewing the literature carefully we found that timing of development of pleural effusion is probably the most important prognostic factor. Those who develop effusion after some time lag form the initial treatment, will have a poor survival (median four months) compared to those who had effusion at the start of the disease.

Anahtar kelimeler

Plevral efüzyon Ölümle sonuçlanma Yaşlı Kadın Erkek Orta yaşlı Multipl miyelom

🔖

Bu Makaleye Atıf Yap

ATTILI, S., ULLAS, B., LAKSHM, D., BAPSY, P. P., LAKSHM, K. C., Govind, K., DASAPPA, L., ELREFI, S. K., ANUPAM, G. (2007). Malignant myelomatous pleural effusion-Is onset of effusion a new prognostic factor?. Turkish Journal of Hematology, Cilt: 24 - Sayı: 4, 182–186. https://ajindex.com/articles/413027

📄 Tam Metin PDF Okuyucu

Yeni Sekmede Aç ↗

↗Yeni Sekme

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

Kamble R, Wilson CS, Fassas A. Malignant pleural effusion of myeloma: Prognostic factors and outcome. Leuk Lymph 2005;46:1137-42
Ghosh S, Gopal R, Advani SH. Myelomatous pleural effusion. J Assoc Physicians India 2006;54:738-9
Crespo Valades E, Espinosa de los Monteros Garde MJ. Myelomatous plural effusion. An Med Interna 2005;22:550-1
Ulubay G, Eyuboglu FO, Simsek A, Ozyilkan O. Multiple myeloma with pleural involvement: A case report. Am J Clin Oncol 2005;28:429-30
Gogia A, Agarwal PK, Jain S, Jain KP. Myelomatous pleural effusion. J Assoc Physicians India 2005;53:734-6
Kim YM, Lee KK, Oh HS, Park SK, Won JH, Hong DS, Park HS, Park JS, Lee DW. Myelomatous pleural effusion with poor response to chemotherapy. J Korean Med Sci 2000;15:243-6
Kyle R. Diagnostic criteria of multiple myeloma. Hematol Oncol Clin North Am 1992;6:347-58
Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer 1975;36:842-54
Kintzer JS, Rosenow EC, Kyle RA. Thoracic and pulmonary abnormalities in multiple myeloma. Arch Intern Med 1978;138:727-30
Sasser RL, Yam LT, Li C. Myeloma with involvement of the serous cavities. Acta Cytol 1990;34:479-85
Makino S, Yamahara S, Nagake Y, et al. Bence-Jones myeloma with pleural effusion: Response to alpha-interferon and combined chemotherapy. Int Med 1992;31:617-21
Favis EA, Kerman HD, Schildecker W. Multiple myeloma manifested as a problem in the diagnosis of pulmonary disease. Am J Med 1960;28:323-32.